Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Lotus Reports Higher Q1 and New Asthma Drug

publication date: May 22, 2008
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Lotus Pharmaceuticals, Inc. announced a 41% increase in revenues in Q1, though net income was up by a smaller 19%. The company booked $11.7 million in sales, while its profits totaled $1 million or 2 cents per share, fully diluted. Earlier this week, Lotus announced it will pay 48 million RMB ($7 million) to buy the patent and production rights to an asthma medicine, Laevo- Bambutero. More details...

Stock Symbol: (OTCBB: LTUS)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...



ChinaBio® Events
Partner Events

Shanghai, China
November 1-3, 2016

Shanghai, China
October 18-19, 2016

Del Mar, USA
October 1st, 2016

Del Mar, USA
October 1st, 2016

>> More events...